Barclays initiates coverage on Sanofi-Aventis (NYSE: SNY) with a Underweight rating.Analyst Dr. Emmanuel Papadakis comments "With Sanofi back at a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE